fistulas (DAFs) and assessing maturation. We developed a DU simulator and used it to assess the accuracy of volume flow measurements.
Objective: Percutaneous access for endovascular aneurysm repair (P-EVAR) is less invasive compared with surgical access (S-EVAR). It is associated with shorter recovery and fewer wound complications. However, vascular closure devices (VCDs) are costly, and the economic impact of P-EVAR has important implications for resource allocation. The objective of our study was to determine the differences in cost between P-EVAR and S-EVAR.
Methods: We used a decision tree to analyze costs from a payer's perspective during the course of the index hospitalization. Probabilities, relative risks, and mean difference summary measures were obtained from a systematic review and meta-analysis. We modeled differences in surgical site infection, lymphocele, and length of hospitalization. Cost parameters were derived from the 2014 National Inpatient Sample using International Classification of Diseases, Ninth Revision, Clinical Modification codes. Attributable costs were estimated using generalized linear models adjusted by age, sex, and comorbidities. Sensitivity analysis was performed to determine the robustness of the results.
Results: A total of 6876 abdominal and thoracic EVARs were identified. P-EVAR resulted in a cost saving of $751 per procedure. The costs for P-EVAR were $1287 (95% confidence interval [CI], $884-$1835), and the costs for S-EVAR were $2038 (95% CI, $757-$4280). P-EVARs were converted to open in 4.3% of cases. P-EVAR patients had a difference of À1.4 days (95% CI, À0.12 to À2.68) in length of hospitalization at a cost of $1190/day (standard error, $298). The cost saving of P-EVAR was primarily driven by the cost difference in length of hospitalization. In the base case, four VCDs were used per P-EVAR at $200/device. In the two-way sensitivity analysis, P-EVAR was cost saving even when 1.5 times more VCDs were used per procedure and the cost of each VCD was 1.5 times greater (Fig) . In our probabilistic sensitivity analysis, P-EVAR was the cost-saving strategy in 82.6% of 10,000 Monte Carlo simulations when simultaneously varying parameters across their uncertainty ranges.
Conclusions: P-EVAR had lower costs compared with S-EVAR and could result in dramatic cost savings if extrapolated to the number of aortic aneurysms repaired. Our analysis was a conservative estimate that does not account for the improved quality of life after P-EVAR.
Author Disclosures: J. C. Hong: Nothing to disclose; G. K. Yang: Nothing to disclose; B. A. Delarmente: Nothing to disclose; R. Khera: Nothing to disclose; J. Price: Nothing to disclose; J. C. Chen: Cook MedicaldCook Alpha post-market study, collaborator. The most cost-saving strategy is displayed across a range of model parameters. For example, in the base case (average patient), the cost per VCD was $200, and four devices were used per procedure, which lies in the blue area; therefore, percutaneous endovascular aneurysm repair (P-EVAR) is the most costsaving strategy.
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